SAB Biotherapeutics, Inc. (SABS) Profit Margin
SAB Biotherapeutics, Inc. (SABS) net profit margin by fiscal period. Analyze profit margins in Excel with MarketXLS.
Profit Margin Data
| Period | Net Profit Margin |
|---|---|
| 2020-12-31 | 36.42% |
| 2021-12-31 | -28.16% |
| 2022-12-31 | -78.40% |
| 2023-12-31 | -1884.50% |
| 2024-12-31 | -2579.03% |
| 2025-12-31 | N/A |
How SABS compares with sector peers
| Symbol | Company | Net profit margin (latest fiscal year) |
|---|---|---|
| AGIO | Agios Pharmaceuticals Inc. | -764.01% |
| XBIT | XBiotech Inc. | -820.45% |
| ACRS | Aclaris Therapeutics Inc. | -829.58% |
| MNOV | MediciNova Inc. | -2928.78% |
| RFL | Rafael Holdings Inc. Class B | -3328.24% |
These are five companies in the same sector as SABS with a comparable annual net profit margin. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get SAB Biotherapeutics, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Profit_Margin("SABS", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | SABS | $3.79 | -3.56% | 0.20M |
| 3 | ||||
| 4 | ||||
| 5 |